Nanexa AB (publ) (STO:NANEXA)
Sweden
· Delayed Price · Currency is SEK 2.500
+0.055 (2.25%)
Jun 17, 2025, 11:59 AM CET
Nanexa AB Company Description
Nanexa AB (publ) operates as a nanotechnology drug delivery company.
The company operates PharmaShell, a drug delivery system that is an atomic layer deposition. It also develops NEX-22 for the treatment of type 2 diabetes.
Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
Nanexa AB (publ)
| Country | Sweden |
| Founded | 2007 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 13 |
| CEO | David Westberg |
Contact Details
Address: Virdings Allle 32B Uppsala, 75450 Sweden | |
| Phone | 46 18 10 03 00 |
| Website | nanexa.com |
Stock Details
| Ticker Symbol | NANEXA |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0007074166 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David Westberg | Chief Executive Officer |
| Marten Rooth | Co-Founder and Chief Technology Officer |
| Anders Johansson | Co-Founder and Head of Intellectual Property |
| Cecilia Danckwardt-Lilliestrom | Chief Financial Officer |
| Mikael Asp | Head of QA and Special Advisor |
| Joel Hellrup | Head of Pharmaceutical Research & Development |
| Polla Rouf | Head of ALD Research & Development |
| Bridget Lacey B.Sc. | Chief Business Officer |
| Otto Skolling M.Sc | Director of Business Development |